(Q42868038)

8 November 2017

Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector (English)

1 reference

8 November 2017

Michael H Bachmann

2

0 references

Robert W Shafer

series ordinal

5

object named as

Robert W Shafer

1 reference

8 November 2017

Elizabeth C Reuman

1

1 reference

8 November 2017

Vici Varghese

series ordinal

3

1 reference

8 November 2017

W Jeffrey Fessel

series ordinal

4

1 reference

8 November 2017

language of work or name

English

0 references

publication date

16 November 2009

1 reference

Antimicrobial Agents and Chemotherapy

8 November 2017

1 reference

8 November 2017

54

1 reference

8 November 2017

2

1 reference

8 November 2017

934-936

1 reference

Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivo

8 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2812164

Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2812164

Raltegravir with optimized background therapy for resistant HIV-1 infection

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2812164

Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2812164

Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2812164

The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2812164

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2812164

Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2812164

Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2812164

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2812164

Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2812164

16 August 2018

Identifiers

DOI

10.1128/AAC.01345-09

1 reference

8 November 2017

1 reference

8 November 2017

PubMed publication ID

19917747

1 reference